Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy Assessment of Human Amniotic Mesenchymal Stem Cells(hAMSCs) Transplantation in Woman With Diminished Ovarian Reserve (DOR)

NCT04706312 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT04706312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy Assessment of Human Amniotic Mesenchymal Stem Cells(hAMSCs) Transplantation in Woman With Diminished Ovarian Reserve (DOR)
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2021
Completion date
April 30, 2024
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diminished ovarian response